(NASDAQ: SMMT) Summit Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 47.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 43.33%.
Summit Therapeutics's earnings in 2025 is -$921,617,000.On average, 18 Wall Street analysts forecast SMMT's earnings for 2025 to be -$977,825,274, with the lowest SMMT earnings forecast at -$1,079,739,457, and the highest SMMT earnings forecast at -$105,561,952. On average, 17 Wall Street analysts forecast SMMT's earnings for 2026 to be -$760,745,830, with the lowest SMMT earnings forecast at -$1,138,103,752, and the highest SMMT earnings forecast at -$437,732,212.
In 2027, SMMT is forecast to generate -$673,497,164 in earnings, with the lowest earnings forecast at -$1,232,945,731 and the highest earnings forecast at -$429,915,566.